ANAPTYSBIO, INC. Remaining Share Repurchase Authorization
ANAPTYSBIO, INC. (ANAB) had Remaining Share Repurchase Authorization of $106.40 million as of 2025-12-31, per its 10-K filed 2026-03-03.
Financial Statements › Notes › Equity
us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1 · last filed 2026-03-03
- 2025-12-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $106.40M.
- 2025-09-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $9.80M.
- 2025-06-30: Stock Repurchase Program, Remaining Authorized Repurchase Amount $19.50M.
- 2025-03-31: Stock Repurchase Program, Remaining Authorized Repurchase Amount $69.60M.
| Period end | Stock Repurchase Program, Remaining Authorized Repurchase Amount |
|---|---|
| 2025-12-31 | $106.40M 10-K · filed 2026-03-03 |
| 2025-09-30 | $9.80M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $19.50M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $69.60M 10-Q · filed 2025-05-05 |
| 2023-03-31 | $11.50M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |